5 Results for "

advanced malignant melanoma

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "advanced malignant melanoma" in MCE Product Catalog:

Cat. No.: HY-P99781
CAS No.: 1610761-46-0
Synonyms: MLN-1202

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-13743
CAS No.: 84088-42-6
Purity:  99.69%
Synonyms: Linomide; FCF89; ABR212616
Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .
loading...
    loading...
Cat. No.: HY-P992399

Target:  

TNF Receptor NF-κB

Research Areas:  

Cancer

LBL-019 is a humanized IgG1 monoclonal antibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .
loading...
    loading...
Cat. No.: HY-13743R
CAS No.: 84088-42-6
Synonyms: Linomide (Standard); FCF89 (Standard); ABR212616 (Standard)
Roquinimex (Standard) is the analytical standard of Roquinimex (HY-13743). Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .
loading...
    loading...
Cat. No.: HY-108839
CAS No.: 198153-51-4
Synonyms: Ro 25-8310/000
Target:  

IFNAR

Research Areas:  

Infection

Peginterferon alfa-2a (Ro 25-8310/000) is a 40 kDa branched pegylated IFN alfa-2a with antiviral and immunomodulatory activities. Peginterferon alfa-2a binds to the Interferon Receptor on the surface of target cells, induces the formation of ISGF3, and promotes the expression of effector proteins such as interferon-stimulated genes (ISGs) and Mx proteins, thereby exerting sustained antiviral effects. Peginterferon alfa-2a is applicable to research on virus infections associated with chronic hepatitis C and chronic hepatitis B .
loading...
    loading...